Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Open Access

Development of LYTACs via incorporating a nucleolin-targeting and lysosome-directed aptamer

View Full Paper
Ask AI
Bookmark
Share

Authors

FQFang QiuZFZiting FengHCHongzheng Chen

Discussion

Loading...

Member takes

Overview

This study demonstrates development of LYTACs targeting nucleolin and c-Met in tumors, suggesting enhanced degradation of extracellular proteins in rheumatoid arthritis.

Key Points

  • Novel LYTACs engineered using SAPT8 show significant antitumor effects through dual degradation of c-Met and nucleolin.
  • By conjugating aptamers, SAPT8 facilitates targeted lysosomal degradation in both tumor and rheumatoid arthritis environments.
  • The study highlights overcoming limitations in LYTAC development, improving extracellular protein degradation capabilities.
  • Fusion of SAPT8 with VEGFR-2-targeting aptamer effectively suppresses RA-FLS activity, offering therapeutic advancements.

Cite This Study

Qiu et al. (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d6478201ahttps://doi.org/10.1101/2025.08.29.672993
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Engineered Nanovesicles-Based Lysosome-Targeting Protein Degradation Platform (NV-TACs) for Cancer Immunotherapy2026
  2. 2LYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradation2025
  3. 3Small-Molecule Ligands Targeting Lysosome-Shuttling Receptors and the Emerging Landscape of Lysosome-Targeting Chimeras2025
  4. 4HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking2025
  5. 5HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking2025